Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
申请人:Domain Therapeutics
公开号:US11008323B2
公开(公告)日:2021-05-18
The present invention provides novel tricyclic 1,4-benzodiazepinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The tricyclic 1,4-benzodiazepinone derivatives of formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. The present invention further provides tricyclic 1,4-benzodiazepinone derivatives of formula (I) that are modulators of metabotropic glutamate receptors (mGluRs), particularly positive allosteric modulators of mGluRs, and more specifically positive allosteric modulators of mGluR3.
本发明提供了通式(I)的新型三环 1,4-苯并二氮杂卓酮衍生物和含有它们的药物组合物。此外,本发明提供的通式(I)化合物和含有它们的药物组合物可用于治疗和/或预防与谷氨酸能信号传导和/或功能改变相关的病症,和/或可受哺乳动物体内谷氨酸水平或信号传导改变影响的病症。式(I)的三环 1,4-苯并二氮杂卓酮衍生物可作为对谷氨酸敏感的神经系统受体的调节剂,特别是作为代谢谷氨酸受体(mGluRs)的调节剂,这使它们特别适用于治疗和/或预防急性和慢性神经和/或精神疾病。本发明进一步提供了式(I)的三环 1,4-苯并二氮杂卓酮衍生物,它们是代谢型谷氨酸受体(mGluRs)的调节剂,特别是 mGluRs 的正性异位调节剂,更具体地说是 mGluR3 的正性异位调节剂。